Explore

Reuters Reuters
US FDA to hold expert committee meeting to review Moderna's flu vaccine

US FDA to hold expert committee meeting to review Moderna's flu vaccine

May 21 (Reuters) - The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot. Moderna's mRNA-based seasonal flu vaccine is currently under review by the U.S.
Trendline Trendline
Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials, Aiming for Broader Protection

Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials, Aiming for Broader Protection

Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials, Aiming for Broader Protection
Trendline Trendline
Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter
Trendline Trendline
hVIVO Advocates for Human Challenge Trials to Accelerate Vaccine Development

hVIVO Advocates for Human Challenge Trials to Accelerate Vaccine Development

hVIVO Advocates for Human Challenge Trials to Accelerate Vaccine Development
Trendline Trendline
Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast

Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast

Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast
Trendline Trendline
Pfizer Advances Pediatric Pneumococcal Vaccine with Strong Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine with Strong Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine with Strong Phase 2 Results
Trendline Trendline
Bayer Seeks FDA Approval for Kerendia in Type 1 Diabetes, Aiming to Expand Treatment Options

Bayer Seeks FDA Approval for Kerendia in Type 1 Diabetes, Aiming to Expand Treatment Options

Bayer Seeks FDA Approval for Kerendia in Type 1 Diabetes, Aiming to Expand Treatment Options
Trendline Trendline
Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results
Trendline Trendline
Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials for Enhanced Protection

Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials for Enhanced Protection

Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials for Enhanced Protection
Trendline Trendline
CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership
Trendline Trendline
FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment
Trendline Trendline
University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response

University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response

University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response